Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: March 15, 2026
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Journal: Neurology
Published: January 30, 2025
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Journal: Neurology
Published: December 03, 2024
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
Journal: Therapeutic advances in neurological disorders
Published: March 05, 2024
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Journal: Journal of neurology
Published: November 10, 2023
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Journal: Annals of clinical and translational neurology
Published: October 18, 2022
Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis.
Journal: Cell death & disease
Published: June 09, 2022
NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.
Journal: International journal of MS care
Published: January 17, 2022
Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: September 10, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 11, 2021
Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Journal: Therapeutic advances in neurological disorders
Published: April 29, 2021
Last Updated: 09/26/2026